509 related articles for article (PubMed ID: 25453735)
1. [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia].
Samalin L; Ben Gharbia M; Garnier M; Llorca PM
Encephale; 2014 Dec; 40(6):507-17. PubMed ID: 25453735
[TBL] [Abstract][Full Text] [Related]
2. Clinical potential of lurasidone in the management of schizophrenia.
Samalin L; Garnier M; Llorca PM
Ther Clin Risk Manag; 2011; 7():239-50. PubMed ID: 21753886
[TBL] [Abstract][Full Text] [Related]
3. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
[TBL] [Abstract][Full Text] [Related]
4. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
[TBL] [Abstract][Full Text] [Related]
5. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study.
Nasrallah HA; Silva R; Phillips D; Cucchiaro J; Hsu J; Xu J; Loebel A
J Psychiatr Res; 2013 May; 47(5):670-7. PubMed ID: 23421963
[TBL] [Abstract][Full Text] [Related]
6. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
Citrome L
Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634
[TBL] [Abstract][Full Text] [Related]
7. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
Meltzer HY; Cucchiaro J; Silva R; Ogasa M; Phillips D; Xu J; Kalali AH; Schweizer E; Pikalov A; Loebel A
Am J Psychiatry; 2011 Sep; 168(9):957-67. PubMed ID: 21676992
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
[TBL] [Abstract][Full Text] [Related]
9. Lurasidone: a new treatment option for schizophrenia.
Owen RT
Drugs Today (Barc); 2011 Nov; 47(11):807-16. PubMed ID: 22146224
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study.
Citrome L; Cucchiaro J; Sarma K; Phillips D; Silva R; Tsuchiya S; Loebel A
Int Clin Psychopharmacol; 2012 May; 27(3):165-76. PubMed ID: 22395527
[TBL] [Abstract][Full Text] [Related]
11. Lurasidone in schizophrenia: new information about dosage and place in therapy.
Citrome L
Adv Ther; 2012 Oct; 29(10):815-25. PubMed ID: 23001538
[TBL] [Abstract][Full Text] [Related]
12. [Long-term efficacy and safety of lurasidone in the treatment of schizophrenia].
Samalin L; Honciuc M; Llorca PM
Encephale; 2015 Dec; 41(6):541-9. PubMed ID: 26603973
[TBL] [Abstract][Full Text] [Related]
13. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
[TBL] [Abstract][Full Text] [Related]
14. Lurasidone in the treatment of schizophrenia: a critical evaluation.
Bruijnzeel D; Yazdanpanah M; Suryadevara U; Tandon R
Expert Opin Pharmacother; 2015; 16(10):1559-65. PubMed ID: 26111577
[TBL] [Abstract][Full Text] [Related]
15. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension.
Harvey PD; Siu CO; Hsu J; Cucchiaro J; Maruff P; Loebel A
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1373-82. PubMed ID: 24035633
[TBL] [Abstract][Full Text] [Related]
16. Lurasidone: a new drug in development for schizophrenia.
Meyer JM; Loebel AD; Schweizer E
Expert Opin Investig Drugs; 2009 Nov; 18(11):1715-26. PubMed ID: 19780705
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
18. Lurasidone (latuda®): an atypical antipsychotic.
Nolan SF; Roman MW
Issues Ment Health Nurs; 2012 May; 33(5):342-3. PubMed ID: 22545643
[TBL] [Abstract][Full Text] [Related]
19. Lurasidone: an atypical antipsychotic for schizophrenia.
Risbood V; Lee JR; Roche-Desilets J; Fuller MA
Ann Pharmacother; 2012; 46(7-8):1033-46. PubMed ID: 22828971
[TBL] [Abstract][Full Text] [Related]
20. Potential use of lurasidone for the treatment of bipolar psychosis.
Carta MG; Moro MF; Nardi AE; Calabrese JR
Expert Opin Investig Drugs; 2015 Apr; 24(4):575-84. PubMed ID: 25633339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]